Friday, August 14, 2020

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients hospitalised with COVID-19 is now open to enrolment.

The Phase II randomised, double-blind, placebo-controlled trial is enrolling up to 90 patients admitted to hospital with COVID-19 in the UK.

Eligible patients will receive daily oral MRx-4DP0004 or placebo, in addition to standard supportive care.

The primary endpoint of the trial is the mean change in clinical status score as measured by the WHO Ordinal Scale for Clinical Improvement.

In addition, several secondary endpoints assess measures of clinical efficacy including the need for, and duration of, ventilation, in addition to safety and tolerability.

4D pharma’s Live Biotherapeutic MRx-4DP0004 has shown the potential to simultaneously down-regulate specific pathological aspects of the hyper-inflammatory response to viral infection, while maintaining the appropriate anti-viral response.

Both are key factors in the effective treatment of the respiratory symptoms associated with COVID-19, not only for hospitalised patients with more severe disease but potentially also in patients with milder symptoms to prevent disease progression and hospitalisation.

As a Live Biotherapeutic, MRx-4DP0004 is expected to display a favourable safety profile.   In an ongoing asthma study MRx-4DP0004 has demonstrated an excellent safety profile to date.

Particularly in the context of the COVID-19 crisis, the safety of this Live Biotherapeutic is critical, in contrast to the known side-effect profiles of other therapies in clinical trials for COVID-19.

“Reducing hyperinflammation, particularly in the lungs, is key to preventing the exacerbation of symptoms associated with more severe COVID-19. 4D pharma has shown MRx-4DP0004 has the ability to target inflammation in the lungs, potentially reducing the respiratory issues central to COVID-19,” said Dr Alex Stevenson, Chief Scientific Officer of 4D pharma.

“4D pharma aims to use this study to generate robust, meaningful clinical data that will support a safe immunomodulatory Live Biotherapeutic intervention for patients hospitalised with COVID-19.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

Former Scunthorpe Market site to be transformed

The future of Scunthorpe’s High Street is revealed as a radical redevelopment plan for the former market is unveiled. North Lincolnshire Council has submitted the...

150 jobs to be created as gas power station gets expansion go-ahead

More than 150 jobs are to be created after a new open cycle gas turbine (OCGT) power station was granted approval. The Department for Business,...

£1.2m renovation of heritage sites in Hull’s Old Town complete

A developer breathing new life into old buildings in Hull has completed the £1.2m renovation of two historic riverside properties. Allenby Commercial has converted Danish...

Flexible packaging manufacturer expands into new Grimsby facility

Ultimate Group is expanding into another facility at Europarc in Grimsby. The independent flexible packaging manufacturer focused on the food industry has signed a lease...

Work begins on new homes at former hospital site

Lindum has started work on 36 new homes on the site of a former hospital in Spalding. Longhurst Group is developing the former Welland Hospital...

IT firm expands into new York offices

An IT and security specialist has expanded into new office space at Escrick Business Park in York. PowerON, which provides managed IT services and cloud...

Related news

Former Scunthorpe Market site to be transformed

The future of Scunthorpe’s High Street is revealed as a radical redevelopment plan for the former market is unveiled. North Lincolnshire Council has submitted the...

150 jobs to be created as gas power station gets expansion go-ahead

More than 150 jobs are to be created after a new open cycle gas turbine (OCGT) power station was granted approval. The Department for Business,...

£1.2m renovation of heritage sites in Hull’s Old Town complete

A developer breathing new life into old buildings in Hull has completed the £1.2m renovation of two historic riverside properties. Allenby Commercial has converted Danish...

Flexible packaging manufacturer expands into new Grimsby facility

Ultimate Group is expanding into another facility at Europarc in Grimsby. The independent flexible packaging manufacturer focused on the food industry has signed a lease...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close